Immune Repertoire Sequencing Market Size

Immune Repertoire Sequencing Market size was valued at USD 1.22 billion in 2024 and is expected to reach USD 2.87 billion by 2037, expanding at around 6.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of immune repertoire sequencing is assessed at USD 1.36 billion.

The market is primarily driven by the escalating government encouragement for pharmacogenomics-based drug recovery. Furthermore, growth in multiple therapeutic areas such as cardiology, pain management, oncology, infectious diseases, and others is estimated to boost the market expansion in the projected period.

Additionally, the industry has been driven by many organizations seeking answers to biomarkers of the immune system. Mergers and acquisitions are also driving the market. More collaboration, acquisition, and agreement among the market players are majorly contributing to the industry growth. In order to produce effective and creative immunotherapies ArcherDX and Ambry Genetics joined hands in March 2018.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of immune repertoire sequencing is assessed at USD 1.36 billion.

The immune repertoire sequencing market size was valued at USD 1.22 billion in 2024 and is expected to reach USD 2.87 billion by 2037, expanding at around 6.8% CAGR during the forecast period i.e., between 2025-2037. The market growth is propelled by increasing number of launches of novel products, and rising government funding to improve the healthcare infrastructure.

North America industry is set to hold largest revenue share by 2037, due to high health spending, and strong presence of market players in the region.

The major players in the market are Agilent Technologies, Inc, Illumina, Inc., Pacific Biosciences of California, Inc, QIAGEN N.V., Thermo Fisher Scientific, Inc., F. Hoffmann-La Roche AG, Takara Bio, Inc, Oxford Nanopore Technologies, Ltd, BGI Group, Atreca Inc

Immune Repertoire Sequencing Market Size